Blood Pressure in Renal Disease: How to Accomplish the Goal?

Summary The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that initial antihypertensive therapy with benazepril plus amlodipine was superior to benazepril plus hydrochlorothiazide in reducing progression of chronic...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular therapeutics 2012-08, Vol.30 (4), p.193-198
Main Authors: Robles, Nicolás R., Hernandez-Gallego, Roman
Format: Article
Language:English
Subjects:
Albuminuria - epidemiology
Albuminuria - therapy
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Antihypertensive Agents - therapeutic use
Blood Pressure - drug effects
Calcium Channel Blockers - therapeutic use
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - physiopathology
Cardiovascular Diseases - prevention & control
Disease Progression
Diuretics - therapeutic use
Drug Therapy, Combination
Evidence-Based Medicine
Humans
Hypertension
Hypertension - drug therapy
Hypertension - epidemiology
Hypertension - physiopathology
Kidney disease
Kidney Diseases - epidemiology
Kidney Diseases - physiopathology
Kidney Diseases - therapy
Renin-Angiotensin System - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that initial antihypertensive therapy with benazepril plus amlodipine was superior to benazepril plus hydrochlorothiazide in reducing progression of chronic kidney disease as well as cardiovascular morbidity and mortality in renal patients. The renal results of the ACCOMPLISH trial strongly support the recommendation of using calcium channel blockers as second antihypertensive agent added to renin–angiotensin axis‐blocking drugs. This review discusses the validity of these data and their relationship with the cumulative evidence on the effects of calcium antagonists on renal disease progression.
ISSN:1755-5914
1755-5922
DOI:10.1111/j.1755-5922.2010.00260.x